Slowly Signaling G Protein–Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence
Xiaoyan Lin(Indiana University Bloomington), Andrea G. Hohmann(Northeastern University)
Cited by 87
Related Papers
Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal
|Molecular Pharmacology|2018|68
The m <sup>6</sup> A Readers YTHDF1 and YTHDF2 Synergistically Control Cerebellar Parallel Fiber Growth by Regulating Local Translation of the Key Wnt5a Signaling Components in Axons
|Advanced Science|2021|42
Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception
|Neuropharmacology|2024|8
Negative allosteric modulation of cannabinoid CB <sub>1</sub> receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception
|bioRxiv (Cold Spring Harbor Laboratory)|2024|2
Mice lacking the endocannabinoid-synthesizing enzyme NAPE-PLD exhibit sex-dependent dysregulations in responsiveness to oxycodone and a natural reward
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0